Our findings showing CREBZF as a NF‐κB coregulator under overnutrition, coupling with the effects of CREBZF on exacerbated hepatic steatosis and NASH, suggest that targeting CREBZF may represent general benefits in treating metabolic diseases. Here, CREBZF is linked to metabolic disease.